eli lilly glp-1 dominance to seek approval of new weight-loss drug this year Eli Lilly Shows Why the – Eli Lilly Proves Its GLP-1

Medication changes: Do not stop, add, or switch diabetes medicines without prescriber guidance

Episodes Jan 13, 2026 Jan 13, 2026 26 min Host: Darryl S

Some improvements were also observed in terms of their cardiovascular health (Pi-Sunyer, Astrup, Fukuoka)

The individual compounds are unapproved for human therapeutic use in the US and are supplied on a research-use-only basis

Diabetologia 54 , 22632271 (2011)

Molecular Properties Property Value Systematic Name Aib-His-D-2-Nal-D-Phe-Lys-NH Molecular Formula CHNO Molecular Weight 711.85 Da CAS Number 170851-70-4 Structure Class Synthetic pentapeptide Receptor Target GHS-R1a (growth hormone secretagogue receptor type 1a) Development Novo Nordisk (NNC 26-0161) The sequence includes -aminoisobutyric acid (Aib) at position 1, D-2-naphthylalanine (D-2-Nal) at position 3, and D-phenylalanine (D-Phe) at position 4